cms.bioaccessla.com

Tag: Latin America

  • Mexico Hospital Implementation Dossier for High-Cost Medical Devices: A LATAM Market Access Playbook

    Mexico Hospital Implementation Dossier for High-Cost Medical Devices: A LATAM Market Access Playbook

    For a high-cost medical device, regulatory authorization is an entry ticket—not a hospital adoption plan. A hospital may recognize that a device is legally marketable and still hesitate because the clinical pathway is unclear, staff training is underestimated, infrastructure is missing, or the budget impact is difficult to defend. In Mexico, where purchasing and delivery decisions can differ by institution, a sponsor needs an implementation dossier that answers the operational questions behind the procurement question.

    This dossier is especially valuable for a leading MedTech startup entering Latin America with limited local utilization data. It turns a technical product file into a decision tool for clinical leaders, procurement teams, finance officers, and administrators without overstating evidence or assuming that one hospital’s process represents the entire market.

    Separate regulatory readiness from adoption readiness

    Begin with two clearly labeled workstreams. The regulatory file explains safety, performance, intended use, labeling, quality, and the evidence required by the applicable health authority. The implementation dossier explains how the device will be used responsibly inside a Mexican hospital: who selects patients, who operates it, how the procedure fits the care pathway, what resources it consumes, and how outcomes will be monitored.

    Keeping these workstreams connected but distinct prevents two common mistakes. First, a sponsor may present a registration dossier as if it proves economic value. Second, a commercial team may make workflow or outcome claims that are not supported by the approved indication or clinical evidence. Use a claims map that links every statement to its source, population, setting, and level of certainty.

    The five sections of a decision-ready implementation dossier

    1. Clinical value and patient selection. State the unmet need, the intended patient profile, the current care pathway, and the measurable outcome the device is expected to influence. Explain inclusion, exclusion, contraindication, referral, and escalation criteria in language that a hospital team can apply. If evidence comes from another country, identify which assumptions may not transfer to Mexican practice.

    2. Workflow and capacity impact. Map the patient journey from referral to follow-up. Identify procedure time, room type, imaging or laboratory dependencies, staffing, sterile-processing needs, device setup, recovery, and emergency coverage. Include the tasks that happen before and after the procedure; these often determine whether a device can be used at scale.

    3. Training and governance. Define the competencies required for physicians, nurses, technicians, biomedical engineering, and scheduling or procurement staff. Provide a staged plan for initial training, supervised cases, competency confirmation, refresher training, and escalation when performance falls below expectations. Assign ownership for maintenance, software updates, adverse-event reporting, and device accountability.

    4. Budget impact and resource use. Show the acquisition or lease assumption, consumables, service contracts, training, facility changes, staff time, and replacement or downtime exposure. Present a base case and transparent sensitivity ranges rather than a single savings claim. Distinguish costs paid by the hospital from costs borne by patients, payers, or external providers.

    5. Evidence and monitoring plan. Define a small set of clinical, operational, and financial indicators that can be measured from the first cases. Examples include procedure duration, conversion or escalation rate, length of stay, readmission, repeat intervention, consumable use, equipment uptime, and patient-reported outcomes when appropriate. Specify the denominator, data source, review cadence, and action threshold for each measure.

    Use early feasibility evidence to reduce implementation risk

    An early-feasibility or first-in-human study can generate more than safety observations when it is designed with downstream adoption in mind. Capture the workflow details that a hospital will need: setup steps, number and type of staff, training time, procedure interruptions, imaging or laboratory turnaround, resource substitutions, and reasons for protocol deviations. Collect these measures prospectively, with a clear distinction between exploratory findings and validated outcomes.

    For Mexico, add a local-context plan before extrapolating from a foreign study. Ask whether referral patterns, public and private hospital workflows, staffing models, procurement cycles, and follow-up access are comparable. A small local implementation assessment—interviews, workflow mapping, or a supervised evaluation—may reveal barriers that a larger but less relevant dataset misses.

    Market access evidence should also be tailored to the decision-maker. A clinical director may prioritize complications and length of stay. A finance team may need annual case volume, cash-flow timing, and sensitivity to utilization. Procurement may require service-level commitments, training records, warranty terms, and supplier continuity. The dossier should let each audience find the same underlying facts without creating conflicting versions of value.

    Design the dossier for Mexico, then make it reusable across LATAM

    Use a Mexico core with institution-specific annexes. The core should cover intended use, clinical evidence, workflow, training, budget impact, data governance, and monitoring. Annexes can address the hospital’s service line, local procurement format, facility assessment, responsible professionals, language, reimbursement assumptions, and implementation timetable.

    When expanding to Colombia, Brazil, Peru, or Chile, preserve the evidence definitions and calculation methods while adapting the local care pathway and decision process. Do not copy a Mexican price, staffing model, or procurement assumption into another country without documenting the change. The result is a regional evidence architecture that supports credible conversations with hospitals and payers, rather than a collection of disconnected country brochures.

    A high-cost device earns adoption when a hospital can see how it will work on a Monday morning, how its risks will be governed, and how its resource use will be measured. A Mexico hospital implementation dossier makes those answers explicit. It helps a sponsor move from “approved technology” to “managed clinical service,” which is the foundation for sustainable MedTech market access throughout Latin America.

    Frequently asked questions

    Is a hospital implementation dossier the same as a reimbursement dossier?
    No. A reimbursement dossier emphasizes coverage, payment, and health-economic justification. An implementation dossier also covers workflow, staffing, training, infrastructure, governance, and operational monitoring. The two should share evidence but serve different decisions.

    What if the device has limited Mexico-specific outcomes data?
    Label the evidence transparently, identify which findings are transferable, and propose a local measurement plan. Early cases can generate structured workflow and resource-use data without being presented as definitive proof of long-term effectiveness.

    How early should sponsors build the dossier?
    Begin during protocol and evidence planning, not after regulatory authorization. Designing the study to capture workflow, utilization, and patient-centered measures can prevent a later evidence gap when hospitals evaluate adoption.

  • Brazil Clinical Research Completeness Check: The Ethics Acceptance Handoff for LATAM MedTech Studies

    Brazil Clinical Research Completeness Check: The Ethics Acceptance Handoff for LATAM MedTech Studies

    For a MedTech sponsor, submitting a study in Brazil is not the same as starting the review clock. The practical milestone is acceptance of a complete, internally consistent package by the responsible ethics and regulatory reviewers. Missing translations, mismatched device descriptions, unsigned site documents, or an unresolved import assumption can turn a promising first-in-human or early-feasibility plan into a sequence of avoidable clarification cycles.

    A disciplined completeness check is therefore more than an administrative exercise. It is the handoff that converts product development evidence into a reviewable clinical study, while creating a template that can be adapted for Colombia, Mexico, Peru, and other Latin American markets.

    Why the ethics acceptance handoff deserves its own control

    MedTech submissions often fail operationally at the boundary between functions. Regulatory colleagues may work from the latest technical dossier, clinical teams from a revised protocol, and the study site from an older informed-consent form. Each document can look reasonable on its own while the package tells different stories about intended use, patient eligibility, procedure steps, adverse-event management, or follow-up.

    Reviewers usually encounter those differences before the sponsor does. The result may be a request for clarification, a pause while the site confirms capabilities, or a need to retranslate and reapprove participant materials. In an early-stage study, even a short delay can affect investigator availability, equipment scheduling, import planning, and the sponsor’s evidence-generation sequence.

    The handoff should answer one question: can an independent reviewer understand what will happen to which participant, with which investigational device, at which qualified site, and under which safeguards without asking the sponsor to reconstruct the story?

    Build one source of truth before country tailoring

    Start with a controlled study narrative and a document matrix. The narrative should state the device’s intended use in the study, the target population, the procedure, the learning objectives, the known and foreseeable risks, and the stopping or escalation rules. Every country document should be checked against that narrative before translation or submission.

    The matrix should identify the owner, version, approval status, language, and submission destination for at least:

    • Protocol, synopsis, statistical or analysis plan, and risk-management summary.
    • Investigator brochure or device dossier, including configuration, accessories, software version, labeling, and instructions for use.
    • Informed-consent form, participant information sheet, recruitment materials, and compensation language.
    • Investigator qualifications, site facilities, procedure-room controls, emergency coverage, device accountability, and training records.
    • Insurance, indemnity, local representation, data-protection documents, and safety-reporting procedures.
    • Import, customs, storage, calibration, maintenance, and return or destruction instructions for investigational units.

    The objective is not to submit every possible document. It is to prove that the selected documents are sufficient, current, and mutually consistent for the study risk and the reviewing institution.

    A five-gate completeness check for Brazil and LATAM

    Gate 1: identity and version lock. Confirm that the protocol, device description, risk analysis, consent materials, and investigator-facing documents use the same product name, configuration, intended use, and version identifiers. Record the effective date and archive superseded files.

    Gate 2: participant-facing clarity. Test the local-language consent materials with someone who was not involved in drafting them. The text should explain the investigational nature of the procedure, alternatives, foreseeable risks, follow-up, data use, and withdrawal without introducing promises that are absent from the protocol. Reconcile terminology across Portuguese, Spanish, and English source files where a multi-country program is planned.

    Gate 3: site capability evidence. Do not rely on a general hospital profile. Map each protocol-critical step to a named room, trained role, piece of equipment, emergency pathway, sample or image workflow, and backup plan. If a capability is supplied by a neighboring department or external service, document the handoff and availability window.

    Gate 4: logistics and accountability. A device can be clinically ready and still be operationally unavailable. Check importer-of-record responsibilities, shipping documents, storage conditions, serial-number control, calibration, delivery receipt, quarantine, return, and destruction. The same device identity should appear in the dossier, site log, shipment plan, and accountability form.

    Gate 5: query ownership and acceptance evidence. Before filing, assign an owner and response target to every foreseeable question. Maintain a redline log showing what changed after internal review, who approved it, and whether the change affects the protocol, consent, risk assessment, site training, or country annex. Save the acceptance notice and the exact package that was accepted; do not treat a later working draft as the official baseline.

    Turn completeness into a measurable activation advantage

    Track more than submission date. Useful indicators include first-pass completeness, number of clarification cycles, days from query receipt to coordinated response, percentage of documents translated without terminology rework, and the time from acceptance to site readiness. These measures reveal whether a delay is regulatory, clinical, logistical, or simply caused by version control.

    For a regional program, keep a master package and add country annexes for local ethics language, authority forms, importer arrangements, insurance, and site requirements. That approach preserves a consistent safety story without assuming that one country’s acceptance substitutes for another’s. It also makes lessons from the first submission reusable instead of forcing the sponsor to restart document reconciliation for every market.

    The strongest Brazil submission is not the longest one. It is the one in which reviewers, investigators, and participants can see the same study from their respective perspectives. Treating ethics acceptance as a controlled handoff—rather than a ceremonial checkpoint—helps a leading MedTech startup protect its timeline, reduce rework, and generate evidence that remains credible across Latin America.

    Frequently asked questions

    What does “complete” mean for a Brazil MedTech submission?
    It means the reviewing body has the documents and information needed to begin substantive review, with consistent product, protocol, participant-protection, site, and logistics information. Exact requirements depend on the study and reviewing institutions.

    Should the sponsor translate every technical document?
    Translate what reviewers, investigators, and participants must read in the required local language, while maintaining controlled source versions for technical review. Confirm language expectations early rather than translating after a deficiency notice.

    Can the same completeness checklist be used in other Latin American countries?
    Yes, as a master control. Keep the core evidence consistent, then add country-specific authority forms, ethics requirements, local representation, import documents, and site controls instead of assuming identical procedures.

  • FIH Protocol Amendments in Latin America: A Control Plan to Reduce Regulatory Rework

    FIH Protocol Amendments in Latin America: A Control Plan to Reduce Regulatory Rework

    FIH protocol amendments in Latin America are not simply document updates. In an early-stage medical device study, a change to an endpoint, eligibility rule, procedure, or safety assessment can affect the ethics submission, regulatory package, informed consent, site workflow, import documents, and training plan at the same time. When each team reviews the change in isolation, sponsors can lose weeks reconciling versions that were technically correct but operationally inconsistent.

    A controlled amendment process gives a leading MedTech startup a safer way to learn quickly without creating avoidable submission cycles. The goal is not to prevent every change. It is to make the rationale, impact, approvals, and implementation sequence visible before a revised protocol reaches a Latin American authority or study site.

    Why FIH protocol amendments create disproportionate risk

    FIH studies generate new information while the protocol is still proving its assumptions. Early observations may lead a sponsor to clarify a stopping rule, narrow a population, change a follow-up visit, or add a safety measurement. Each decision can be reasonable on its own, yet the combined effect may change the study’s risk profile or the way a site performs a procedure.

    Latin America adds a coordination layer because country and institutional reviews do not always move in the same sequence. Colombia’s clinical-investigation framework, for example, places emphasis on the investigational plan, participant protection, and institutional oversight through its national regulator and participating institutions. Brazil’s evolving clinical-research framework also reinforces the importance of a complete, internally consistent package. A sponsor should therefore treat the amendment as a cross-functional change-control event, not as a new version of a Word file.

    The first decision is classification. Is the change administrative, operational, scientific, or safety-related? Does it alter the primary objective, participant exposure, procedure burden, inclusion and exclusion criteria, statistical assumptions, or the information presented during consent? A short impact statement answering these questions becomes the anchor for every downstream reviewer.

    A five-step control plan for FIH protocol amendments Latin America

    1. Open one amendment record. Assign a unique internal change number, an owner, a decision date, and a short rationale. Record the current approved version and list every affected artifact: protocol, investigator materials, consent form, case-report forms, safety plans, device accountability records, import documentation, and site training. This prevents the common failure mode in which the protocol is updated but a supporting document still describes the previous procedure.

    2. Map the evidence and risk impact. Explain what new information triggered the change and whether it reduces, increases, or leaves unchanged the foreseeable risk to participants. For a procedure change, identify new equipment, staffing, emergency coverage, or competency requirements. For an eligibility change, review recruitment feasibility and whether the consent discussion needs new language. Keep the analysis proportional, but do not skip it because the amendment appears minor.

    3. Run a country and institution matrix. Create a row for each Latin American country and each participating institution. For every row, identify the authority or ethics body that must review the change, whether the amendment can be submitted in parallel, which documents require local language updates, and what must happen before implementation. The matrix should distinguish approval, acknowledgement, notification, and site activation. Those are different milestones and should never be collapsed into one “approved” status.

    4. Freeze the release package. Use a single source package with a clean protocol, tracked-changes version, amendment summary, revised consent language, updated supporting documents, and a version crosswalk. Add a release checklist requiring clinical, regulatory, quality, medical, data, and site-operations sign-off. A simple rule helps: no site receives an operational instruction until the effective version and the applicable local approval status are confirmed.

    5. Close the loop after approval. Record the effective date for each country and site, then confirm retraining, re-consent, database updates, document replacement, and audit-trail completion. The amendment is not implemented when a letter arrives; it is implemented when the right participants, investigators, and systems are operating from the same approved instructions. A short post-implementation review can capture whether the change produced the intended safety or data-quality benefit.

    Designing an amendment dossier reviewers can follow

    A reviewer should be able to understand the change without comparing every line of two long documents. Start with a one-page executive summary: what changed, why it changed, which participants are affected, which risks were reassessed, and what approvals are requested. Follow with a table showing old language, new language, rationale, and affected documents. Add the supporting evidence that informed the decision, but keep unrelated background out of the core package.

    Use consistent terminology across the protocol, consent form, investigator brochure or device information, and site instructions. If the amendment changes a visit window, the schedule of assessments and case-report form should use the same definition. If it changes a safety threshold, the monitoring plan and escalation pathway should repeat the same threshold. Consistency is a practical signal that the sponsor understands its own risk controls.

    For country execution, prepare a local annex rather than rewriting the global rationale several times. The annex can identify the applicable authority, institutional sequence, language needs, local contact, and implementation date. This approach protects the scientific core of the amendment while giving each country team the detail needed for compliant execution.

    FAQ: FIH protocol amendments in Latin America

    When should a sponsor notify sites about a planned amendment?

    Share a controlled planning notice when sites need to prepare, but do not authorize the changed procedure until the applicable review and implementation conditions are met. Early communication can reserve training time and prevent avoidable scheduling disruption.

    Should an amendment be submitted in every Latin American country?

    Not automatically. The decision depends on the change, the local rules, and the status of the study in each country. A country matrix should document whether the action is approval, acknowledgement, notification, or no filing, with a clear rationale and owner.

    How can sponsors reduce amendment-related delays?

    Reduce avoidable delay by classifying the change early, using one evidence-based impact assessment, freezing a complete release package, and tracking country and site implementation separately. The cross-functional readiness gate for FIH submissions provides a related framework for aligning teams before filing.

    For regulatory context, sponsors can consult INVIMA’s clinical-investigation information and Brazil’s Law No. 14.874/2024. Requirements should be confirmed with local regulatory and ethics experts before a submission is made.

  • Radiopharma Trials In Latin America: Designing Operations For 6 Hour Half-Lives

    Radiopharma Trials in Latin America: Designing Operations for 6-Hour Half-Lives

    Primary keyword: radiopharmaceutical clinical trial logistics Latin America

    Radiopharmaceuticals are one of the most promising frontiers in oncology, but they force clinical teams to operate on a different clock. An industry announcement noted that because these materials decay in hours rather than months, the operational window for patient administration is extremely narrow, leaving very little margin for error.

    Latin America can be an attractive region for radiopharma development, but sponsors need an operating model that is designed for short half-lives, just-in-time supply, and site readiness. This article outlines a practical framework for radiopharmaceutical clinical trial logistics in Latin America—without duplicating country-specific checklists already covered elsewhere.

    1) Start with the “decay clock” and design backward

    Radiopharma operations should start with physics. If a product’s usable window is measured in hours, then every downstream step must be planned backwards from the scheduled administration time:

    • Manufacturing slot and release testing (including potential rework)
    • Packaging and validated temperature control
    • Transportation and customs risk (for cross-border moves)
    • Site receipt, verification, and patient preparation

    Operational principle: Do not treat shipment as a “logistics problem.” Treat it as part of the dosing procedure.

    2) Build site readiness around minute-by-minute workflows

    In many conventional trials, small workflow inefficiencies are tolerated. In radiopharma, they can cause missed windows or protocol deviations.

    • Define a standard receiving workflow: who signs, where it is stored, and how identity and activity are verified.
    • Train for exceptions: delayed flights, partial shipments, or last-minute patient rescheduling.
    • Synchronize departments: nuclear medicine, pharmacy, imaging, and the clinical team must share one operational plan.

    3) Manage supply risk with redundancy and “plan B” lanes

    A radiopharma webinar announcement highlighted just-in-time manufacturing and strict cold-chain requirements as differentiators from standard investigational products, and emphasized that protocol pivots and supply disruptions are expected rather than rare. In Latin America, the right mitigation strategies can include:

    • Backup transport lanes: pre-qualified couriers and alternate airport routing options.
    • Site network design: cluster sites to reduce travel time from production to administration.
    • Inventory philosophy: you cannot “stockpile” short half-life product, so redundancy must come from operations, not storage.

    4) A practical operating model for Latin America radiopharma programs

    To make logistics predictable, sponsors can standardize four elements across countries:

    • Readiness checklists: site staffing, equipment calibration, temperature monitoring, and emergency procedures.
    • Scheduling discipline: patient scheduling should be tied to confirmed manufacturing slots and transport windows.
    • Visibility: live tracking of manufacturing status, shipment milestones, and site receipt confirmation.
    • Contingency triggers: pre-defined thresholds for when to reschedule a patient, re-route a shipment, or activate an alternate site.

    When these elements are standardized, the operational advantage of Latin America—experienced research sites and growing infrastructure—can translate into reliable execution, not just theoretical speed.

    5) Data integrity and chain-of-custody: treat the dose as a specimen

    With radiopharmaceuticals, sponsors should document the product journey with the same rigor used for biospecimens. This reduces deviations and supports inspection readiness.

    • Time-stamped handoffs: manufacturing release, courier pickup, arrival at site, and administration time.
    • Temperature and shielding logs: continuous monitoring, out-of-range triggers, and documented corrective actions.
    • Identity checks: verify patient, product label, and activity at the moment of administration.

    Practical tip: Create a single-page “dose administration record” that sites can complete in real time and upload the same day.

    6) Regulatory and customs planning: design for border reality

    Latin America is not one regulatory system. Cross-border moves can introduce unpredictable delays, so logistics planning should assume variability and reduce exposure wherever possible.

    • Prefer in-country or near-country production when feasible: shorter transit times reduce decay loss.
    • Pre-clear documentation: align on import documentation, labeling, and receiver information well before first shipment.
    • Schedule around local constraints: weekends, holidays, and airport cutoffs matter more when the product lifetime is measured in hours.

    When sponsors plan for these constraints, Latin America sites can deliver high-quality execution even for time-sensitive protocols.

    FAQ: Radiopharmaceutical clinical trial logistics Latin America

    • Why are radiopharmaceutical trials harder to run than conventional trials?
      Because many products decay in hours, the operational window is extremely narrow and sites must coordinate manufacturing, shipping, and patient readiness with little margin for error.
    • What is the most common operational failure mode?
      Missed administration windows caused by delays in manufacturing release, transportation, site workflow issues, or patient no-shows.
    • How can Latin America sites reduce missed dosing windows?
      By building standardized readiness checklists, aligning patient scheduling with shipment timelines, and designing contingency plans for transportation or manufacturing disruptions.

    Planning a radiopharma study in Latin America? bioaccess® can help sponsors design site networks, readiness plans, and startup execution models that reduce missed dosing windows.

  • Radiopharmaceutical Trials In Latin America: A Logistics Readiness Framework For Sponsors

    Radiopharmaceutical Trials in Latin America: A Logistics Readiness Framework for Sponsors

    Radiopharmaceutical and theranostics programs have accelerated globally, but their clinical execution has a unique constraint: you are not only running a trial — you are running a time-sensitive supply chain. In Latin America, that supply chain can be a competitive advantage when it is planned well, and a critical risk when it is treated as an afterthought.

    This article offers a practical logistics readiness framework for sponsors planning radiopharmaceutical clinical trials in Latin America. The goal is to help clinical and operational leaders identify failure modes early and design a deployment plan that matches the physics, not just the protocol.

    Why radiopharmaceutical logistics is different

    Radiopharmaceutical trials have “hard” operational constraints: isotope half-life, radiation safety controls, qualified hot lab capacity, imaging standardization, and tightly coordinated shipment windows. In addition, sponsors may need to coordinate with multiple stakeholders — manufacturer, radiopharmacy, courier, customs brokers, hospital nuclear medicine teams, and regulators — where each handoff introduces risk.

    Because of these constraints, a strong sponsor question is: Can we execute the chain reliably, repeatedly, and compliantly for every subject?

    A logistics readiness framework (4 pillars)

    Use the following four pillars to assess readiness before site activation.

    Pillar 1: Isotope supply and contingency planning

    • Primary supply route: Define the manufacturing source, batch release timing, and shipment windows that match enrollment cadence.
    • Secondary route: Identify a backup route for disruptions (transport restrictions, manufacturing delays, flight changes).
    • Buffer strategy: For short half-life isotopes, “buffer” often means operational flexibility (multiple shipment windows) rather than inventory.

    Pillar 2: Regulatory and permit architecture

    • Import permits and documentation: Confirm what must be approved before the first shipment, and what can be handled per-shipment.
    • Labeling and chain-of-custody: Ensure labels, documentation, and custody logs satisfy both radiation safety and clinical trial requirements.
    • Waste and radiation safety: Map disposal pathways and responsibilities with each site to avoid last-minute operational blocks.

    Pillar 3: Site infrastructure and workflow maturity

    • Hot lab capability: Validate equipment, personnel qualification, and SOPs for receipt, preparation, and administration.
    • Scheduling discipline: Radiopharmaceutical administration is scheduling-sensitive. Sites need reliable slot control and patient preparedness workflows.
    • Adverse event readiness: Ensure emergency procedures and escalation pathways are documented and rehearsed.

    Pillar 4: Imaging, dosimetry, and data standardization

    • Imaging protocol consistency: Standardize acquisition parameters and timing relative to administration.
    • Calibration and QA: Establish calibration schedules and quality checks to reduce inter-site variability.
    • Data transfer and review: Define secure transfer pathways, central reads (if used), and turnaround expectations.

    Common failure modes — and how to prevent them

    • Enrollment outpaces supply planning: Align recruitment targets to realistic shipment cadence and site throughput.
    • Customs and documentation surprises: Create country-specific shipment playbooks and run a “first shipment rehearsal.”
    • Inconsistent imaging: Use standardized checklists and training, and consider centralized QA early.
    • Site capability overestimation: Validate the workflow in practice, not only on paper. A site can be clinically excellent and still operationally unready for radiopharmaceutical constraints.

    FAQ

    1) What should we assess first when choosing Latin American countries for radiopharmaceutical trials?
    Start with isotope availability routes, hot lab capacity, and the country’s ability to support compliant import and radiation safety workflows. If those are weak, other advantages will not compensate.

    2) Are logistics risks higher in Latin America than in the U.S. or EU?
    They are different. Risks often relate to cross-border shipment orchestration and variability in infrastructure by site. With the right planning and experienced operators, sponsors can build reliable execution pathways.

    3) How do we prevent schedule failures due to isotope half-life constraints?
    Design your operational plan around the isotope clock: confirmed shipment windows, controlled scheduling, backup routes, and rapid communication workflows across all parties.

    Bottom line: Radiopharmaceutical clinical trials reward operational maturity. Sponsors that treat logistics as a core part of trial design — not a downstream task — can unlock faster, more reliable execution across Latin America.

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, now set by statutory review clocks (Disposición 7516/25 for drug studies, Disposición 969/1997 for device studies), is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (drug-study review clocks, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost and regulator throughput (for device studies, a legal maximum of 90 business days from filing under Disposición 969/1997, versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols early: Disposición 7516/25 governs drug studies, and device studies fall under Disposición 969/1997, which gives ANMAT up to 90 business days from filing to decide. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

    Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

    For MedTech and Biopharma teams considering Latin America, Brazil has historically been seen as a high-potential but hard-to-predict jurisdiction for early-stage clinical trials. That uncertainty can inflate budgets and push teams toward smaller, single-country feasibility strategies.

    Brazil’s Law No. 14.874/2024 introduced a clear constraint: for primary petitions for clinical trials with humans (for marketing authorization purposes), the health analysis may not exceed 90 business days. The law also describes how additional information requests affect the clock.

    This article explains what the 90-business-day window means in practical terms, how sponsors can build a sponsor-ready activation timeline around it, and what pitfalls still cause delays even in a more predictable regime.

    What the law changed (and what it did not)

    The most sponsor-relevant shift is that a defined review window reduces planning ambiguity. A predictable maximum review duration enables better parallelization: ethics preparation, site contracting, and supply chain setup can be scheduled against a more reliable regulatory milestone.

    However, a legal review window does not automatically eliminate operational delays. Sponsors still need to manage:

    • Dossier completeness and consistent technical documentation
    • Ethics sequencing across institutions and committees
    • Import readiness for investigational product shipments
    • Site activation capacity (training, contracting, scheduling)

    In other words, the “clock” helps the regulatory portion of the critical path—but the rest of the program still needs a plan.

    Translating “90 business days” into an activation timeline

    Sponsors often underestimate how different business days can be from calendar days when building a global timeline. A pragmatic approach is to create three layers:

    • Regulatory layer: submission, review window, and potential information request handling
    • Ethics layer: committee submissions and approvals (often overlapping but not identical to regulatory steps)
    • Operations layer: contracts, budget approvals, training, and supply chain readiness

    A sponsor-ready planning template for Brazil should include:

    • Week 0–2: lock document ownership, finalize submission-ready dossier, confirm translation requirements, and run an internal quality check.
    • Week 2–4: submit to the relevant bodies; initiate site contracting and budget cycles in parallel.
    • During review window: implement a weekly “readiness review” covering import documentation, device labeling alignment (if applicable), training scheduling, and monitoring plans.
    • Upon clearance + ethics alignment: initiate first shipment, conduct site initiation, and begin enrollment.

    The objective is to avoid a common failure mode: regulatory clearance arrives, but operations are not ready—so the team loses the predictability advantage that the defined window provides.

    How information requests can still create delays

    Even with a defined maximum window, sponsors should plan for information requests. The practical lesson is to assume that the first submission must be as complete as possible, and that the team must be ready to respond quickly.

    To reduce the chance of delays:

    • Assign a single submission owner responsible for consistency across protocol, investigator brochure (if applicable), device dossier, and administrative documents.
    • Create a rapid-response package before submission: technical specs, risk management summaries, labeling variants, and manufacturing documentation.
    • Pre-brief sites on likely follow-up questions so responses do not stall waiting for institutional input.

    Speed matters because information requests often pause progress until the sponsor responds, and slow responses can negate the benefits of the defined review period.

    Why Brazil’s predictability matters for LATAM multi-country strategy

    For some early-stage teams, Brazil may now be easier to include in a multi-country Latin America strategy when paired with other jurisdictions. The strategic value is not only speed—it is credibility of planning. When leadership teams can explain why the timeline is realistic, financing, vendor contracting, and site commitments become easier.

    To maximize the benefit, sponsors should treat Brazil as one component of a LATAM activation architecture:

    • Define a country sequencing strategy (which country starts first and why)
    • Standardize document templates across countries (with country annexes)
    • Build a supply chain plan that can support staggered activations without stockouts

    When done well, the result is not just a faster first patient in; it is a trial program that is easier to scale.

    FAQ

    Does the 90-business-day window guarantee approval?

    No. A defined window is about timing, not outcome. Sponsors still need a complete, well-justified dossier and an operational plan that supports ethics and site readiness.

    Should early-stage sponsors wait for Brazil before activating other LATAM countries?

    Not necessarily. Many sponsors can run activities in parallel across countries. The right choice depends on device complexity, supply chain constraints, and how quickly the sponsor can support multiple site activations.

    What is the single biggest mistake sponsors make with “faster” regulatory timelines?

    Assuming that regulatory speed automatically creates operational speed. The winning approach is to use predictability to parallelize work—contracts, training, and import readiness—so the program is ready when clearance arrives.

    Bottom line: Brazil’s Law 14.874/2024 gives sponsors a more predictable planning horizon. The teams that benefit most will be the ones that treat the regulatory window as a scheduling tool—and execute the operational readiness plan in parallel.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • Radiopharmaceutical Trials In Latin America: A Practical Logistics Playbook For Short‑Lived Isotopes

    Radiopharmaceutical Trials in Latin America: A Practical Logistics Playbook for Short‑Lived Isotopes

    Radiopharmaceutical trials are a different operational species. The science may be the differentiator, but logistics is the constraint: short half-lives, radiation safety requirements, time-sensitive patient scheduling, and multi-agency approvals for cross-border movement. Sponsors who treat radiopharma like a conventional IMP supply chain often learn the hard way—through missed dosing windows and unusable shipments.

    1) Start with the physics: half-life turns every delay into lost dose

    If your isotope decays in hours, you don’t have “shipping delays”—you have immediate product shrinkage. The planning unit is not days; it is minutes. That means your protocol and operations plan must specify allowable time windows for production, release testing, transport, and administration, and it must include decision rules for when to cancel, reschedule, or reroute.

    • Define the decay budget: the maximum elapsed time from end of synthesis to administration.
    • Map critical control points: handoffs where delays occur (release, airport acceptance, customs, last-mile, site receiving).
    • Build a “go/no-go” clock: so everyone knows when continuing becomes scientifically meaningless.

    2) Cross-border execution in Latin America: permits, airports, and handoffs

    In many Latin America routes, the main risk is not distance—it is variability: airline handling, airport screening queues, and country-by-country documentation requirements. The most reliable programs treat each shipment like a rehearsed procedure rather than an ad hoc package drop.

    Internal execution experience across the region repeatedly highlights that reliability improves when sponsors standardize these elements:

    • Packaging qualification: validated temperature/containment performance and clear labeling for every handler.
    • Documentation kit: standardized set of shipping papers, permits, and emergency contacts—pre-reviewed by local experts.
    • Chain of custody: timestamped handoffs with escalation triggers.
    • Site receiving SOP: pre-briefed staff, equipment readiness, and immediate QC/receipt checks.

    3) Site readiness: the hidden bottleneck

    Even a perfect shipment fails if the site is not ready. A radiopharma site must coordinate pharmacy/nuclear medicine teams, imaging, patient prep, and administration windows. The sponsor’s job is to make this coordination easy and repeatable.

    Recommended site readiness checklist:

    • Weekly capacity confirmation: confirm patient slots, staff coverage, and scanner availability.
    • Receiving drill: simulate the shipment arrival, handoff, and documentation review.
    • Waste and incident plan: clear procedures for contamination, spills, and disposal aligned with local requirements.
    • Back-up scheduling: a pre-identified alternative window when a shipment is delayed but still usable.

    4) Resilience without runaway cost: design a tiered contingency plan

    Not every shipment needs the most expensive option. Create a tiered plan:

    • Tier 1 (default): primary carrier + primary route, with standard packaging and standard site workflow.
    • Tier 2 (moderate disruption): alternate flight routings and a backup last-mile provider.
    • Tier 3 (critical disruption): rapid escalation options, including premium routing and emergency re-release windows.

    This structure helps you maintain reliability while containing cost—and it makes decision-making faster in the moment.

    FAQ

    Why is radiopharma logistics harder than standard drug trials?
    Because many isotopes decay quickly, small delays in production, packaging, flight connections, or site preparation can reduce delivered activity and impact dosing windows.

    What is the most common operational failure mode?
    Misaligned schedules across cyclotron/production, export/import clearances, airport handling, last-mile transport, and site readiness—creating avoidable holds that consume half-life.

    How do sponsors add resilience without exploding cost?
    Use a tiered contingency plan: alternate flight routings, backup depots, standardized packaging, qualified second-source carriers, and rehearsed site receiving checklists; reserve higher-cost options only for critical shipments.

    Need help executing radiopharma studies in Latin America? bioaccess® supports sponsors with regional operational planning, site activation support, and logistics coordination built for time-sensitive programs.

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. For drug studies, Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), sets business-day review clocks for clinical pharmacology protocols, with ethics committee review running in parallel to ANMAT agency review rather than in sequence. Device studies follow a different rule: Disposición 969/1997, the regime for medical technology clinical studies, gives ANMAT up to 90 business days from filing to decide, with the clock paused while objections are open. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    The bioaccess® sample budget puts a first-in-human study in Latin America at about $430K for 20 subjects with a minimally invasive device and about $1.32M for 10 subjects with a surgical implant (illustrative, not a quote; see bioaccessla.com/sample-budget-fih-trial-latin-america). For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25 (drug studies), Disposición 969/1997 (device studies), the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol (under Disposición 969/1997 for a device study, or Disposición 7516/25 for a drug study) runs the two reviews in parallel rather than in sequence, so the Argentine arm can begin generating bridge data without waiting on the U.S. file. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a parallel Argentine arm into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. Disposición 7516/25 is operative for drug studies, and device studies run under Disposición 969/1997. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations: